AstraZeneca Gets FDA Approval for Fasenra Auto-Injector Pen

Date : 10/04/2019 @ 11:42AM
Source : Dow Jones News
Stock : Astrazeneca Plc (AZN)
Quote : 7258.0  29.0 (0.40%) @ 4:35PM
Astrazeneca share price Chart

AstraZeneca Gets FDA Approval for Fasenra Auto-Injector Pen

AstraZeneca (NYSE:AZN)
Historical Stock Chart

3 Months : From Sep 2019 to Dec 2019

Click Here for more AstraZeneca Charts.

By Chris Wack


AstraZeneca (AZN) said Friday that the U.S. Food and Drug Administration has approved the self-administration of Fasenra benralizumab in a pre-filled, single-use auto-injector, the Fasenra Pen.

The pharmaceutical company said the approval is supported by data from the Phase III GRECO trial and the Phase I AMES trial, which achieved their primary objective of usability and pharmacokinetic exposure, respectively. The company said the safety and tolerability of Fasenra in these trials were consistent with the established profile of the medicine.

AstraZeneca says Fasenra self-administration and the Fasenra Pen are also approved in the European Union. Fasenra is currently approved as an add-on maintenance treatment for severe eosinophilic asthma in the U.S., EU, Japan and other countries.


Write to Chris Wack at


(END) Dow Jones Newswires

October 04, 2019 07:27 ET (11:27 GMT)

Copyright (c) 2019 Dow Jones & Company, Inc.
Your Recent History
Gulf Keyst..
FTSE 100
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V:us D:20191209 03:38:18